(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
A significant Phase 2/3 clinical trial has been launched to evaluate a new approach for treating heart damage associated with Duchenne Muscular Dystrophy. The study will involve early diagnosis of heart damage through cardiac magnetic resonance imaging and treatment with the anti-fibrosis drug eplerenone. Learn more about the study.
A new law allows international physicians to participate in supervised hands-on training at Ohio's academic medical centers.Read More »
Cincinnati Children's leads multicenter study of an intensified treatment for neuroblastoma.Read More »
An experimental drug dubbed "Rhosin" blocks cancer cell growth and promotes neurite development in lab tests.Read More »
Early studies in mice show that augmenting a protein pathway in the body's blood-making system protects against radiation poisoning.Read more »
A protein called thrombospondin activates a protective pathway that prevents heart cell damage in mice.Read more »
Watch this presentation on pediatric obesity to earn CME credit.Watch the video »
Register today for Pediatric Insights, our monthly e-newsletter for physicians. Receive the latest information on clinical advancements, research updates and news from Cincinnati Children's.
Subscribe Now >>
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.